Predictors of response to tofacitinib or etanercept in a phase 3 randomized, noninferiority study in patients with moderate to severe chronic plaque psoriasis

被引：0

作者：

Lambert, Jo ^{[1
]}

Strohal, Robert ^{[2
]}

de la Cruz, Claudia ^{[3
]}

Thaci, Diamant ^{[4
]}

Bachelez, Herve ^{[5
]}

Iversen, Lars ^{[6
]}

Rottinghaus, Scott ^{[7
]}

Tallman, Anna ^{[8
]}

Tan, Huaming ^{[7
]}

Berstein, Gabriel ^{[9
]}

机构：

[1] Ghent Univ Hosp, Ghent, Belgium

[2] Fed Acad Teaching Hosp Feldkirch, Feldkirch, Austria

[3] Clin Dermacross, Santiago, Chile

[4] Univ Med Sch, Comprehens Ctr Inflammat Med, Schleswig Holstein Campus, Lubeck, Germany

[5] Univ Paris Diderot, Sorbonne Paris Cite, Hop St Louis, AP HP, Paris, France

[6] Aarhus Univ Hosp, Aarhus C, Denmark

[7] Pfizer Inc, Groton, CT USA

[8] Pfizer Inc, New York, NY USA

[9] Pfizer Inc, Cambridge, MA USA

来源：

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2016年 / 74卷 / 05期

关键词：

D O I：

暂无

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

3386

引用

页码：AB263 / AB263

页数：1

共 50 条

[21] Efficacy of tofacitinib for the treatment of nail psoriasis: two 52-week phase 3 studies in patients with moderate to severe plaque psoriasis
Merola, Joseph
Tatulych, Svitlana
Kaur, Mandeep
Lan, Shuping
Mallbris, Lotus
Mamolo, Carla
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2015, 135 : S9 - S9
[22] Efficacy of tofacitinib for the treatment of nail psoriasis: two 52-week Phase 3 studies in patients with moderate to severe plaque psoriasis
Kaur, M.
Merola, J.
Tatulych, S.
Mamolo, C.
Lan, S.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2016, 30 : 81 - 81
[23] Efficacy of tofacitinib for the treatment of nail psoriasis: Two 52-week phase 3 studies in patients with moderate to severe plaque psoriasis
Merola, Joseph
Tatulych, Svitlana
Mamolo, Carla
Lan, Shuping
Mallbris, Lotus
Kaur, Mandeep
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (05) : AB248 - AB248
[24] Effects of etanercept treatment on lipid profile in patients with moderate-to-severe chronic plaque psoriasis: a retrospective cohort study
Lestre, Sara
Diamantino, Filipa
Veloso, Luis
Fidalgo, Ana
Ferreira, Ana
EUROPEAN JOURNAL OF DERMATOLOGY, 2011, 21 (06) : 916 - 920
[25] Efficacy and safety of briakinumab vs. etanercept and placebo in patients with moderate to severe chronic plaque psoriasis
Gottlieb, A. B.
Leonardi, C.
Kerdel, F.
Mehlis, S.
Olds, M.
Williams, D. A.
BRITISH JOURNAL OF DERMATOLOGY, 2011, 165 (03) : 652 - 660
[26] Etanercept in patients with moderate to severe plaque psoriasis: a retrospective case cohort analysis
Perera, G.
Fonia, A.
Smith, C.
Barker, J. N. W. N.
BRITISH JOURNAL OF DERMATOLOGY, 2009, 161 : 26 - 27
[27] Efficacy and safety of oral tofacitinib in North American patients with moderate to severe plaque psoriasis: Pooled analyses of data from randomized phase 3 studies
Korman, Neil J.
King, Brett
Wolk, Robert
Tan, Huaming
Kaur, Mandeep
Robertson, Debbie
Langley, Richard
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (05) : AB247 - AB247
[28] Pharmacokinetics, Immunogenicity, and Efficacy of Etanercept in Pediatric Patients With Moderate to Severe Plaque Psoriasis
Langley, Richard G.
Kasichayanula, Sree
Trivedi, Mona
Aras, Girish A.
Kaliyaperumal, Arunan
Yuraszeck, Theresa
Gibbs, John
Gibbs, Megan
Kricorian, Greg
Paller, Amy S.
JOURNAL OF CLINICAL PHARMACOLOGY, 2018, 58 (03): : 340 - 346
[29] Baseline characteristics of patients with moderate to severe plaque psoriasis: post-hoc analysis of response to etanercept
Gisondi, Paolo
Girolomoni, Giampiero
de Vlam, Kurt
Al Hammadi, Anwar
Carneiro, Sueli
Arenberger, Petr
Gallo, Gaia
Jones, Heather
Hsu, Ming-Ann
Ferdousi, Tahmina
Szumski, Annette
Chhabra, Amit
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2015, 135 : S26 - S26
[30] Effect of tofacitinib withdrawal and re-treatment on patient-reported outcomes: results from a Phase 3 study in patients with moderate to severe chronic plaque psoriasis
Griffiths, C. E. M.
Vender, R.
Sofen, H.
Kircik, L.
Tan, H.
Rottinghaus, S. T.
Bachinsky, M.
Mallbris, L.
Mamolo, C.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2017, 31 (02) : 323 - 332

← 1 2 3 4 5 →